Introduction
Lung cancer is the most common cause of cancer death worldwide. The incidence of lung adenocarcinoma (AD) has increased recently, and AD has become the most common type of lung cancer (Devesa et al., 2005) . Cigarette smoking is the major risk factor for lung cancer. It attributes to 90% of male and 80% of female lung cancer patients in the western countries. However, in East Asia, smoking is much less prevalent in women than men by 5% versus 50% in general population and by 11% versus 80% in lung cancer patients (Ando et al., 2003; Liaw et al., 2005; Thun et al., 2008; Scagliotti et al., 2009) . Risk factors for lung cancer in Asian never-smokers include previous pulmonary diseases, family cancer history, environmental tobacco smoke, cooking fumes exposure, ingested arsenic and human papillomavirus infection (Chen et al., 2004a, b; Yu et al., 2006; Tse et al., 2009; Wang et al., 2009b) . Furthermore, the abnormal molecular signatures in lung cancer tissue are very different when smokers and non-smokers are compared (Carolan et al., 2008; Tan et al., 2009) . Therefore, lung cancer in non-smokers is considered to be a different disease (Bryant and Cerfolio, 2007; Subramanian et al., 2007) , and the etiology of nonsmoking lung cancer is very unclear. Thus, early prevention and treatment are important issues for lung AD, especially in non-smokers. Identifying molecular mechanisms for lung AD in non-smokers will greatly facilitate these aims.
Aryl hydrocarbon receptor (AhR) is a ligand-activated transcription factor belonging to the Per-AhR nuclear translocator (Arnt)-Sim family. Various exogenous chemicals, such as benzo(a)pyrene and 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), bind to AhR with high affinity and activate AhR (Denison and Nagy, 2003) . Cigarette smoke also activated AhR in vitro and in vivo (Kasai et al., 2006) . Liganded AhR translocates into the nucleus and dimerizes with the Arnt. The AhR-Arnt complex further binds to xenobiotic response elements and these regulate expression of various genes, such as members of the cytochrome P450 families and phase II enzymes (Whitlock, 1999) . Activated AhR not only has a key role in tumor initiation but also in tumor progression (Dietrich and Kaina, 2010) . For example, the TCDDactivated AhR pathway has been found to enhance the invasion of gastric cancer cells, and urothelial carcinoma cells (Peng et al., 2009; Ishida et al., 2010) . Matsumoto et al. (2007) also showed that AhR is essential for carcinogenesis of airborne particulates in mice.
Recent reports have started to elucidate the function of AhR in the absence of any exogenous ligands (Barouki et al., 2007) . For example, Hayashibara et al. (2003) showed that AhR is constitutively expressed and is active in human adult T-cell leukemia. Shimba et al. (2002) showed that overexpression of AhR promoted human lung cancer cells' proliferation. Previously, we have shown that AhR is highly expressed in lung AD as well as in bronchioalveolar carcinoma, which is considered to be carcinoma in situ (Lin et al., 2003; Su et al., 2009) . Furthermore, interference with AhR expression reduces colony formation by human lung AD cells (Chang et al., 2007a) . Therefore, we propose that AhRmediated biological responses may enhance the development of lung AD.
Interleukin-6 (IL-6) is a pleiotropic cytokine regulated by nuclear factor-kB (NFkB) and has a role in tumor progression (Smith et al., 2001; Trikha et al., 2003; Zerbini et al., 2003; Dijsselbloem et al., 2004) . For example, cyclooxygenase-2-induced IL-6 expression has been found to prevent the apoptosis of non-small cell lung carcinoma (NSCLC) cells (Dalwadi et al., 2005) . Besides, Gao et al. (2007) demonstrated that a reduction in IL-6 expression decreased growth of lung cancer cells. AhR ligands, such as benzo(a)pyrene (Chen et al., 2005; Chang et al., 2007b) and TCDD (Puga et al., 2000) , are known to activate various NFkB signaling pathways. But, sometimes, the cross talk between NFkB and liganded AhR mutually suppressed downstream gene expression (Tian, 2009) . Especially, the effect of AhR ligands on IL-6 expression is still controversial (Jensen et al., 2003; DiNatale et al., 2010) .
By examining the expression of AhR, CYP1A1, RelA and IL-6 in lung specimen, we surprisingly found that the association between AhR, RelA and IL-6 occurred significantly in non-smoking lung cancer specimens. We thus hypothesize that in the absence of exogenous ligand AhR overexpression in lung cancer cells should increase IL-6 expression via a modulation of NFkB activation with mechanism different from ligand activated AhR (Figure 1 ). We demonstrated that unliganded AhR associated with RelA, without Arnt or p50, and increased NFkB activity, as well as IL-6 expression, in lung cancer cells. Here, we present a novel mechanism for AhR-enhanced IL-6 expression in non-smoking lung cancer patients. AhR may be a potential molecular target for the prevention or treatment of lung cancer in non-smokers.
Results
Association of clinical features with expression of cytosolic and nuclear AhR, CYP1A1, nuclear RelA and IL-6 in NSCLC The expression of AhR, CYP1A1, RelA and IL-6 was examined in 127 AD and 73 squamous-cell-carcinoma patients. Both AhR and RelA are transcription factors and undergo nuclear translocation after activation. Cytosolic AhR is associated with downstream gene expression in AD (Chang et al., 2007a; Wang et al., 2009a) and therefore both cytosolic and nuclear AhR expression were measured and reported. More than 90% of lung tumor cells highly expressed cytosolic RelA, but only nuclear RelA was measured and reported in this study. CYP1A1 and IL-6 were mainly expressed in the cytosol. As shown in Table 1 , the frequencies of AhR Figure 1 The possible protein complexes for AhR-regulated IL-6 expression, in the presence and absence of exogenous ligands. overexpression in the cytosol and nucleus occurred in 48 and 32% of the NSCLC patients. Using univariate analysis, high AhR expression was more common in females, associated with AD or with never smokers compared with in males, associated with squamous-cell carcinoma or with ever smokers (data not shown). After adjustment for gender, tumor type and smoking status, a high expression of cytosolic AhR was still more common in AD than in squamous-cell carcinoma (Table 1) . High CYP1A1 expression was more prevalent in ever smokers than in never smokers ( Table 1) . Expression of nuclear AhR, nuclear RelA or IL-6 was not associated with any clinical feature.
Correlation between cytosolic/nuclear AhR with nuclear RelA and IL-6 in NSCLC We hypothesized that AhR is a key regulator of IL-6 gene expression and further analyzed the correlation of AhR expression with RelA, CYP1A1 and IL-6 expression in these specimens. We found that cytosolic and nuclear AhR correlated well with nuclear RelA and IL-6, but CYP1A1 only correlated with cytosolic AhR (Table 2) . After stratification based on smoking history, nuclear AhR was still well correlated with nuclear RelA and IL-6 in both ever smokers and never smokers (Table 2) . On the other hand, cytosolic AhR correlated with CYP1A1 in ever smokers, but correlated with nuclear RelA and IL-6 in never smokers (Table 2 ). In general, nuclear RelA and IL-6 expression correlated with both cytosol and nuclear AhR in NSCLC. However, CYP1A1 only correlated with cytosolic AhR. It is well known that AhR is constitutively expressed in the cytosol of cultivated epithelial cells and is transiently translocated into the nucleus following treatment with ligands, where it interacts with dioxin response element (DRE) and then returns to the cytosol (Pollenz, 2002) . Therefore, it is reasonable that elevated AhR expression in the cytosol of tumor cells is significantly correlated with CYP1A1 expression in ever smokers who have been exposed to exogenous AhR ligands from cigarette smoke. Thus, it seems likely that the mechanism for the correlation of AhR with nuclear RelA/IL-6 expression might be different between smokers and non-smokers ( Figure 1 ).
AhR expression modulates IL-6 expression in human lung cells
Our results for lung cancer specimens showed that AhR expression positively correlated with IL-6 expression in non-smoking lung cancer patients. In vitro, overexpression of AhR in BEAS-2B and H1355 cells significantly increased the IL-6 mRNA level in cells as well as the IL-6 protein level in the culture medium ( Figure 2a ). Consistent reduction of AhR expression was obtained in two stable AhR RNA interference clones, si1414-6 and si1414-7, and IL-6 mRNA, and protein levels were also significantly lower in si1414-6 and si1414-7 compared with wild-type and vector control cells (Figure 2b ). Similarly, transient interference targeting AhR significantly reduced IL-6 mRNA levels in H1355 cells (data not shown). These results suggest that AhR expression positive modulates IL-6 expression in human lung cells.
AhR upregulates IL-6 expression via modulation of NFkB activity As IL-6 is regulated by NFkB (Aggarwal, 2004) , we further investigated whether AhR modulated IL-6 expression via increased NFkB activity. Indeed, we demonstrated that overexpression of AhR increased NFkB reporter activity in H1355 cells, and interference with AhR expression significantly reduced NFkB reporter activity in H1355 cells (Figure 3a) . Furthermore, the NFkB inhibitor Bay117085 and interference with RelA expression greatly abolished the increase in IL-6 mRNA levels caused by AhR overexpression 44 (40) 37 (34) 76 (69) 38 (35) 84 (76) Never smoker 86
49 (57) 25 (29) 47 (54) 36 (42) 58 (67) Abbreviations: AD, adenocarcinoma; AhR, aryl hydrocarbon receptor; IL-6, interleukin; NSCLC, non-small cell lung carcinoma; SQ, squamouscell carcinoma. AhR/NFjB for IL-6 expression in lung AD P-H Chen et al ( Figure 3b ). Some studies have shown that the ligand activation of the AhR signaling pathway is usually accompanied by NFkB activation (Chen et al., 2005; Chang et al., 2007b) . The question remains as to whether AhR overexpression activates the classical AhR signaling pathway (resulting in increased CYP1A1 expression via DRE), which then cross talks with the NFkB pathway in human lung cells (Figure 1 ). Here, we found that AhR overexpression failed to increase either DRE reporter activity or CYP1A1 mRNA levels ( Figure 3c ). These results suggest that AhR expression upregulates IL-6 expression via a modulation of NFkB activity without the involvement of the DRE-mediated responses.
AhR overexpression increases nuclear translocation of RelA without association with p50 AhR ligand-induced NFkB activation is usually associated with the nuclear translocation of RelA and p50 (Camacho et al., 2005) . In our following experiments, we investigated whether AhR overexpression also stimulated the nuclear translocation of RelA and p50 as previous reported in ligand-activated AhR (Figure 1 ). Utilizing an immunofluorescence assay, we found that both TCDD treatment and AhR overexpression resulted in the nuclear translocation of both RelA and AhR (Figure 4) . Surprisingly, only TCDD treatment, but not AhR overexpression, caused the nuclear translocation of p50 (Figure 4 ). Similar results were observed using western immunoblotting (Figure 5a ). This raises the question as to whether RelA and AhR associated with each other during nuclear translocation. Using the immunoprecipitation assay, we showed that AhR was associated with HSP90, RelA, p50, and IkBa in the cytosol (Figure 5b ). After TCDD treatment, AhR was associated with Arnt in the nucleus (Figure 5b ), and RelA was associated with p50 in the nucleus (Figures 4  and 5c ). However, in the absence of ligand, AhR overexpression resulted in an association of AhR with RelA, but not of AhR with Arnt, in the nucleus (Figures 5b and c) . The absence of a nuclear association of AhR with Arnt after AhR overexpression is consistent with the absence of DRE-regulated responses (Figure 3c ). Thus, it appears that ligandactivated AhR and overexpressed AhR modulate NFkB activation in different mechanisms. Overexpressed AhR is associated with RelA and modulates RelA nuclear translocation (Figure 7 ).
The AhR/RelA complex is bound to the kB element of the IL-6 promoter It has been demonstrated that RelA/p50 complex binds the kB element of the IL-6 promoter and upregulates IL-6 expression (Vanden Berghe et al., 2006) . The question is whether the AhR/RelA complex performs a similar function to the RelA/p50 complex. In H1355 cells, TCDD treatment increased the association of RelA and p50 on the kB element of IL-6 promoter ( Figure 6 ), and thus it appears that TCDD enhances the formation of the RelA/p50 complex, which then binds to the kB element and increases IL-6 expression. On the other hand, AhR overexpression in H1355 cells increased the association of RelA with AhR without involving p50 and the complex then also binds to the kB element; AhR interference in si1414-6 cells reduced these associations. These results suggested that AhR positively modulates the association of the AhR/RelA complex with the kB element (Figure 7) . Consistent with the increased NFkB activity caused by AhR overexpression, the association of AhR/RelA complex on the kB element would seem to increase NFkB activity, resulting in upregulation of IL-6 expression.
Discussion
Identifying unique molecular mechanisms among never smokers with lung cancer is becoming one of the focuses of lung cancer research. Elevated IL-6 expression is common to many cancers. In our present study, we demonstrated that AhR, without exposure to a ligand, associates with RelA, which then positively modulates NFkB activity and then upregulates IL-6 expression in human lung cells. The association was also significantly revealed in non-smoking lung cancer patients. Thus, we identified a new mechanism for lung tumorigenesis in non-smokers. Therefore, AhR becomes a potential molecular target for the prevention or treatment of lung cancer in never smokers.
In NSCLC patients, 32% of them express AhR in the nuclei of tumor cells. However, surprisingly, nuclear expression of AhR was not correlated with CYP1A1 expression in NSCLC patients, regardless of smoking status. Notwithstanding this, nuclear expression of AhR might have other functions, such as increasing IL-6 expression as it does in our present study. This suggests that the nuclear expression of AhR is not a consequence of exogenous ligand-activated nuclear translocation of AhR. The presence of endogenous AhR ligands has been proposed by some studies (Oesch-Bartlomowicz et al., 2005; Mukai and Tischkau, 2007) ; however, the binding sites for endogenous and exogenous molecules on the AhR protein might be different. Another possibility is that AhR fails to be exported out of the nucleus correctly. The exact mechanism involved in the nuclear localization of AhR remains unsolved.
Although both liganded and unliganded AhR are able to upregulate IL-6 expression via increasing NFkB activity, the detailed mechanisms are different (Figure 7) . TCDD activated (liganded) AhR increases the binding of the RelA/p50 complex to the IL-6 promoter. It is believed that TCDD increases NFkB activity by generating reactive oxygen species (Dhar et al., 2002; Lin et al., 2007) . On the other hand, unliganded AhR associates with RelA without involving p50 and then binds to the NFkB site of the IL-6 promoter. A similar association between AhR and RelA proteins on c-myc promoter has been reported in breast cancer cells (Kim et al., 2000) . The exact domains mediating the interaction of AhR with RelA as well as those involved in binding to other proteins associated the AhR/RelA complex remain unclear and further investigation is needed.
Our results show that AhR overexpression increased NFkB activity and enhanced the association of the AhR/RelA complex with NFkB site on the IL-6 promoter ( Figure 7) . Epigenetic regulation, such as phosphorylation or acetylation, has an important role in NFkB activity and functionality. p300/CBP is a coactivator for AhR and NFkB and has histone acetyltransferase activity (Tian, 2009) . p300/CBP is also able to increase acetylation of RelA, which prolongs NFkB-DNA binding (Chen et al., 2001) . On the other hand, histone deacetylase has been reported to reduce RelA acetylation and suppressed NFkB-regulated gene expression (Chen et al., 2001) . We also observed that AhR overexpression reduced histone deacetylase activity (data not shown). Nonetheless, some studies in other cells have reported that the AhR/RelA interaction negatively regulates gene expression by increasing acetylation status (Ke et al., 2001; Tian, 2009 ). Thus, it seems likely that the positive effect of AhR/RelA on NFkB activity might be cell-type specific.
Our results also show that AhR overexpression reduced the level of IkBa protein in the cytosol and nucleus of H1355 cells. Upon NFkB activation, cytosolic IkBa is phosphorylated, ubiquitinized and then degraded by the ubiquitin-proteasome system. After IkBa degradation, the cytosol IkBa is rapidly replenished by newly synthesized IkBa, which is transcriptionally regulated by activated nuclear NFkB. Large amounts of newly synthesized IkBa may exceed the capacity of the cytosol NFkB proteins and thus permit free IkBa to accumulate in the nucleus (Arenzana-Seisdedos et al., 1997). In the nucleus, IkBa will associate with RelA; the complex is then exported out of the nucleus and thus terminates transcriptional activation. Ohtake et al. (2007) reported that AhR is an atypical E3 ubiquitin ligase that is required for ubiquitination. Thus, overexpression of AhR in cells might increase the E3 ubiquitin ligase activity of AhR, which, in turn, might reduce IkBa protein levels. However, more evidence is required to reach the conclusion that IkBa protein is a target for the E3 ubiquitin ligase activity of AhR.
Regardless of the mechanisms involved, both liganded and unliganded AhR upregulates IL-6 expression in lung cancer cells. Disrupting AhR signaling or expression therefore might reduce the expression of IL-6, which is known to have multiple roles in tumorigenesis. Some flavonoids present in plants have already been demonstrated to block ligand-activated AhR signaling and therefore these substances have potential therapeutic usefulness in cancer prevention (Fukuda et al., 2007; Izawa et al., 2008; Lu et al., 2008) . Such flavonoids or other targeted drugs may be useful for the prevention or treatment of lung cancer patients where there is AhR involvement.
Materials and methods

Study subjects and human tissue microarray constructions
Retrospectively, 200 paraffin tissue blocks, obtained from 200 NSCLC patients (stages I-IV) treated at the Chung Shan Medical University Hospital in Taichung, Taiwan, were collected to construct two tissue microarrays. These lung cancer tissues were obtained during surgery or by core biopsy and were then immediately fixed with 10% buffered neutral formalin and embedded in paraffin. For this study, only squamous-cell carcinoma and AD as diagnosed according to the World Health Organization classification were selected. Other tumor types were excluded because of the small number of cases. One of the authors, Dr Han Chang, reviewed all the studied cases and selected the area of the tumor for sampling. This study was approved by the Institutional Review Board of the Chung Shan Medical University Hospital, Taichung, Taiwan.
Clinical features
Clinical features, namely, gender, age, cancer stage and smoking status at diagnosis, were verified from the hospital medical records or by telephone interview. Smoking status was assessed as either ever smokers or never smokers. Never smokers were defined as those who had never smoked previously. Individuals who were currently smoking, or had ever smoked, were counted as smokers.
Immunohistochemistry
Immunohistochemistry was performed as previously described (Lin et al., 2003) . The primary antibodies consisted of antiAhR (Biomol, Plymouth Meeting, PA, USA), anti-NFkB p65 subunit (clone 12H11, Millipore, Temecula, CA, USA), anti-IL-6 (clone H183, Santa Cruz Biotechnology, Santa Cruz, CA, USA) and anti-CYP1A1 (clone H-70, Santa Cruz Biotechnology).
Assessment of AhR, RelA (p65), IL-6 and CYP1A1 immunohistochemistry The immunoreactivity for AhR, RelA, IL-6 and CYP1A1 were evaluated via immunostaining of the lung tumor and bronchi- AhR/NFjB for IL-6 expression in lung AD P-H Chen et al olar cells in the tissue sections. Assessment of AhR (Biomol) immunohistochemistry was done as previously described (Chang et al., 2007a) . For RelA (Millipore), IL-6 (H-183, Santa Cruz Biotechnology) and CYP1A1 (H-70, Santa Cruz Biotechnology) evaluation, the immunoreactivity of the tumor or bronchiolar cells was compared with those in the adjacent stoma that showed negative immunoreactivity. When the RelA, IL-6 and CYP1A1 immunostaining intensity of the lung tumor or bronchiolar cells (>10% of cells in the tissues) was stronger than the adjacent stroma, this sample was considered to have positive expression. The percentage of highly expressing cells was then calculated from at least 300 examined cells.
Plasmids and RNA interference
To establish the AhR overexpression plasmid, human AhR complementary DNA was inserted into pcDNA3 together with two FLAG sequences 99 bp upstream of the start site. For AhR RNA interference, the short-hairpin AhR template (5 0 -GCCAC TCACCTCTTCAGAA-3 0 ) was cloned into an inducible vector (pSingle-tTS-shRNA) and then transfected into H1355 for selection of stable clones as described previously (Wang et al., 2009a) . RelA expression was transiently interfered with SignalSilence NF-kB p65 siRNA II (Cell Signaling, Danvers, MA, USA).
Cell culture and transient transfection
Human bronchial epithelial cell line BEAS-2B cells were cultured in LHC-9 (Gibco, Grand island, NY, USA). The human lung AD cell line H1355 cells were cultured in 5% fetal calf serum/RPMI1640 (Gibco) supplemented with penicillin/ streptomycin. For transient transfection, 8 mg of expression vector (for 6 cm dish) was used to transfect cells using Lipofectamine 2000 (Invitrogen, Grand island, NY, USA). The transfection efficiency was about 80%.
Quantitative real-time reverse transcriptase PCR Total RNA was extracted using the TRI reagent (MRC, Cincinnati, OH, USA). A total amount of 3 mg of total RNA was subjected to a reverse transcription step using the ABI High-Capacity cDNA Archive Kit (ABI, Foster City, CA, USA). Real-time PCR quantification was then performed using SYBR GREEN Master Mix (ABI) and TaqMan universal PCR Master Mix (Roche, Branchburg, NJ, USA). Glyceraldehyde-3-phosphate dehydrogenase was used for normalization. The primers and probes for AhR, CYP1A1 and glyceraldehyde-3-phosphate dehydrogenase were from the Assay-on-Demand Gene Expression Assay Mix (ABI). The primers for IL-6 were 5 0 -CCGGGAACGAAAGAGAA GCT-3 0 and 5 0 -CGCTTGTGGAGAAGGAGTTCA-3 0 .
Enzyme-linked immunosorbent assay H1355 cells, AhR RNA interference stable clones or AhR transiently transfected H1355 cells were seeded into six-well dishes. The culture medium was then collected at 48 h. IL-6 concentration was determined using the Human IL-6 ELISA kit (BD Biosciences, San Diego, CA, USA) according to the manufacturer's instructions.
Reporter gene assay AhR expression vector was co-transfected with pNF-kB-Luc (Stratagene, La Jolla, CA, USA) or 4 Â DRE-TATA-Luc (give from Dr Tsui-Chun Tsou, Division of Environmental Health and Occupational Medicine, National Health Research Institutes, Zhunan, Taiwan). Inducible short-hairpin AhR vector was co-transfected with pNF-kB-Luc (Stratagene). At 48 h after transfection, a luciferase assay was performed as described previously (Chang et al., 2007b) .
Immunofluorescence The H1355 cells with or without AhR overexpression were fixed with 10% formaldehyde on a cover glass for 6 h. After permeabilizing with phosphate-buffered saline with Tween 20 (1 Â phosphate-buffered saline with 0.2% Tween 20) for 1 h, the cells were incubated with AhR (Biomol), RelA (Millipore) or p50 (Cell Signaling) antibody for 24 h at room temperature and then incubated with FITC (Molecular Probes, Eugene, OG, USA) or TRITC (Zymed, Grand island, NY, USA) for 1 h. After washing, the cells were incubated with 4 0 ,6-diamidino-2-phenylindole for 5 min. Finally the fluorescence was imaged using fluorescence microscopy (Leica DMRXA, Wetzlar, Germany).
Western immunoblotting
Western blotting was performed as previously published (Chang et al., 2007a) with anti-AhR (Biomol), anti-Flag (Sigma, Louis, MO, USA), anti-HSP90 (Assay Designs, Ann Arbor, MI, USA), anti-Arnt (H-172, Santa Cruz Biotechnology), anti-RelA (C-20, Santa Cruz Biotechnology), anti-p50 (Cell Signaling), anti-IkBa (C-21, Santa Cruz Biotechnology), anti-a-tubulin (Genetex, Hsinchu City, Taiwan) and anti-LaminB (C-20, Santa Cruz Biotechnology) antibodies. The protein bands were detected by chemiluminescence.
Chromatin immunoprecipitation assay
Cell lysates were collected from H1355 cells, AhR-overexpressed H1355 cells and AhR RNA interference stable clones. Each lysate was incubated with 1 mg of anti-AhR (Biomol), antiRelA (C-20, Santa Cruz Biotechnology) or anti-p50 (Cell Signaling) antibodies and PureProteome Protein A Magnetic Bead (Millipore) for chromatin immunoprecipitation assay. Chromatin immunoprecipitation analysis was performed using a procedure with the following modifications (Sharma and Fondell, 2002) . The chromatin immunoprecipitation and input DNA were used for the real-time PCR analysis. The primers of kB element on IL-6 promoter were 5 0 -AGACATGCCAAAG TGCTGAG-3 0 and 5 0 -ATGTGGGATTTTCCCATGAGTC-3 0 . Real-time PCR products were also run on an 8% polyacrylamide gel electrophoresis and analyzed by ethidium bromide staining.
Statistical analysis
Pearson's w 2 -test was performed to examine the association between the biomarkers AhR, RelA, CYP1A1 and IL-6 and the clinical features. Multivariate logistic regression testing was performed to determine the association between expressions of biomarkers. Differences between groups of in vitro experiments were compared using the Student's t-test. Differences in data were considered statistically significant at Po0.05.
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